- Home
- UAL vs ALNY Comparison
UAL vs ALNY Comparison
Compare UAL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAL
- ALNY
- Stock Information
- Founded
- UAL 1934
- ALNY 2002
- Country
- UAL United States
- ALNY United States
- Employees
- UAL N/A
- ALNY N/A
- Industry
- UAL Air Freight/Delivery Services
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- UAL Consumer Discretionary
- ALNY Health Care
- Exchange
- UAL Nasdaq
- ALNY Nasdaq
- Market Cap
- UAL 31.6B
- ALNY 33.2B
- IPO Year
- UAL N/A
- ALNY 2004
- Fundamental
- Price
- UAL $107.38
- ALNY $246.27
- Analyst Decision
- UAL Strong Buy
- ALNY Buy
- Analyst Count
- UAL 17
- ALNY 24
- Target Price
- UAL $102.95
- ALNY $299.09
- AVG Volume (30 Days)
- UAL 5.2M
- ALNY 629.6K
- Earning Date
- UAL 01-21-2025
- ALNY 02-13-2025
- Dividend Yield
- UAL N/A
- ALNY N/A
- EPS Growth
- UAL N/A
- ALNY N/A
- EPS
- UAL 8.30
- ALNY N/A
- Revenue
- UAL $55,994,000,000.00
- ALNY $2,094,795,000.00
- Revenue This Year
- UAL $6.58
- ALNY $24.87
- Revenue Next Year
- UAL $6.87
- ALNY $18.53
- P/E Ratio
- UAL $12.94
- ALNY N/A
- Revenue Growth
- UAL 6.67
- ALNY 21.54
- 52 Week Low
- UAL $37.02
- ALNY $141.98
- 52 Week High
- UAL $110.92
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- UAL 64.42
- ALNY 50.98
- Support Level
- UAL $104.38
- ALNY $232.82
- Resistance Level
- UAL $110.15
- ALNY $256.93
- Average True Range (ATR)
- UAL 3.50
- ALNY 8.85
- MACD
- UAL 0.46
- ALNY 1.98
- Stochastic Oscillator
- UAL 81.50
- ALNY 49.48
About UAL United Airlines Holdings Inc.
United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.